BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease? Diabet Med. 2001;18:329-332. [PMID: 11437866 DOI: 10.1046/j.1464-5491.2001.00492.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gallo M, Ruggeri RM, Muscogiuri G, Pizza G, Faggiano A, Colao A; NIKE Group. Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any? Cancer Treat Rev 2018;67:1-9. [PMID: 29746922 DOI: 10.1016/j.ctrv.2018.04.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
3 Lombardi A, Tomer Y. Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress. J Autoimmun 2017;80:48-55. [PMID: 28238527 DOI: 10.1016/j.jaut.2017.02.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
4 Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21(1): 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
5 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(5): 586-600 [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
6 Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, Sobel E, Atkinson MA, Clare-Salzler MJ. Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production. J Immunol 2014;193:1024-34. [PMID: 24973447 DOI: 10.4049/jimmunol.1303230] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
7 Calvaruso V, Craxì A. Immunological alterations in hepatitis C virus infection. World J Gastroenterol 2013; 19(47): 8916-8923 [PMID: 24379616 DOI: 10.3748/wjg.v19.i47.8916] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
8 Oka R, Hiroi N, Shigemitsu R, Sue M, Oshima Y, Yoshida-Hiroi M. Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review. Clin Med Insights Endocrinol Diabetes. 2011;4:39-45. [PMID: 22879793 DOI: 10.4137/cmed.s7815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
9 Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H, Maruyama T, Hanafusa T; Research Committee on Type 1 Diabetes of the Japan Diabetes Society. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care 2011;34:2084-9. [PMID: 21775762 DOI: 10.2337/dc10-2274] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
10 Migliarini B, Piccinetti CC, Martella A, Maradonna F, Gioacchini G, Carnevali O. Perspectives on endocrine disruptor effects on metabolic sensors. Gen Comp Endocrinol 2011;170:416-23. [PMID: 21130769 DOI: 10.1016/j.ygcen.2010.11.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
11 Buchbinder D, Steinberg G, Linetsky M, Casillas J. Moyamoya in a child treated with interferon for recurrent osteosarcoma. J Pediatr Hematol Oncol 2010;32:476-8. [PMID: 20562650 DOI: 10.1097/MPH.0b013e3181e5e1db] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Lo Y, Chang S, Sheng W, Hung C, Chang S. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature: . European Journal of Gastroenterology & Hepatology 2009;21:478-81. [DOI: 10.1097/meg.0b013e328317f4c8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Tosone G, Borgia G, Gentile I, Cerini R, Conte MC, Orlando R, Piazza M. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol 2007;44:167-9. [PMID: 17721757 DOI: 10.1007/s00592-007-0259-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
14 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
15 Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB;  Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39:2-17. [PMID: 16884964 DOI: 10.1016/j.dld.2006.06.008] [Cited by in Crossref: 164] [Cited by in F6Publishing: 147] [Article Influence: 10.3] [Reference Citation Analysis]
16 Schnabel CA, Fineberg SE, Kim DD. Immunogenicity of xenopeptide hormone therapies. Peptides 2006;27:1902-10. [DOI: 10.1016/j.peptides.2006.01.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
17 Chehadeh W, Lobert PE, Sauter P, Goffard A, Lucas B, Weill J, Vantyghem MC, Alm G, Pigny P, Hober D. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon. J Virol 2005;79:13882-91. [PMID: 16254324 DOI: 10.1128/JVI.79.22.13882-13891.2005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
18 Ma Y, Yan WW. Chronic hepatitis C virus infection and post-liver transplantation diabetes mellitus. World J Gastroenterol 2005; 11(39): 6085-6089 [PMID: 16273631 DOI: 10.3748/wjg.v11.i39.6085] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
19 Sallie R. Replicative homeostasis II: influence of polymerase fidelity on RNA virus quasispecies biology: implications for immune recognition, viral autoimmunity and other "virus receptor" diseases. Virol J 2005;2:70. [PMID: 16115320 DOI: 10.1186/1743-422X-2-70] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
20 Kim JD, Sherker AH. Antiviral therapy: role in the management of extrahepatic diseases. Gastroenterology Clinics of North America 2004;33:693-708. [DOI: 10.1016/j.gtc.2004.04.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
21 Kotani R, Nagata M, Imagawa A, Moriyama H, Yasuda H, Miyagawa J, Hanafusa T, Yokono K. T lymphocyte response against pancreatic beta cell antigens in fulminant Type 1 diabetes. Diabetologia 2004;47:1285-91. [DOI: 10.1007/s00125-004-1441-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
22 Sylvestre DL, Disston AR, Bui DP. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat. 2003;10:467-470. [PMID: 14633182 DOI: 10.1046/j.1365-2893.2003.00456.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
23 Stewart TA. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev 2003;14:139-54. [PMID: 12651225 DOI: 10.1016/s1359-6101(02)00088-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 3.6] [Reference Citation Analysis]
24 Hilkens CMU, Schlaak JF, Kerr IM. Differential Responses to IFN-α Subtypes in Human T Cells and Dendritic Cells. J Immunol 2003;171:5255-63. [DOI: 10.4049/jimmunol.171.10.5255] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 4.2] [Reference Citation Analysis]
25 Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58. [PMID: 12969081 DOI: 10.1046/j.1365-2036.2003.01681.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
26 Sasso FC, Carbonara O, Di Micco P, Coppola L, Torella R, Niglio A. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy. Br J Clin Pharmacol. 2003;56:238-239. [PMID: 12895200 DOI: 10.1046/j.0306-5251.2003.01854.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
27 Altintas A, Alici Y, Melikoğlu M, Siva A. Arthritis during interferon beta-1b treatment in multiple sclerosis. Mult Scler 2002;8:534-6. [PMID: 12474998 DOI: 10.1191/1352458502ms852xx] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]